Fulgent Genetics (FLGT) CEO receives stock awards and tax share withholding

Rhea-AI Filing Summary

Fulgent Genetics, Inc. director and CEO Ming Hsieh reported multiple equity-related transactions in the company’s common stock. On February 24, 2026, he acquired shares at a price of $0.00 per share through grants and vesting of restricted stock units tied to performance milestones and service-based conditions.

On the same date, shares were also disposed of at $23.09 per share, and on February 23, 2026 at $23.01 per share, to satisfy tax withholding obligations triggered by those vestings, rather than open‑market sales. The filing also shows significant indirect holdings through the Dynasty Trust, The Ming Hsieh Trust, a Uniform Transfers to Minors Act account, and an immediate family member’s account, with varying levels of voting and dispositive power as described in the footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hsieh Ming

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		2,167(1)	D	$23.01	797,054	D
Common Stock	02/24/2026		A		19,067(2)	A	$0	816,121	D
Common Stock	02/24/2026		A		39,802(3)	A	$0	855,923	D
Common Stock	02/24/2026		A		59,276(4)	A	$0	915,199	D
Common Stock	02/24/2026		F		10,230(5)	D	$23.09	904,969	D
Common Stock	02/24/2026		F		21,354(6)	D	$23.09	883,615	D
Common Stock	02/24/2026		F		31,760(7)	D	$23.09	851,855	D
Common Stock	02/24/2026		A		69,294(8)	A	$0	921,149	D
Common Stock								7,895,115	I	By Trust(9)
Common Stock								220,816	I	By Trust(10)
Common Stock								1,000	I	Uniform Transfer to Minor Account(11)
Common Stock								1,000	I	By Immediate Family(12)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

2. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023.

3. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024.

4. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025.

5. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023.

6. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024.

7. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025.

8. Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

9. Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.

10. Securities held by The Ming Hsieh Trust (the "Hsieh Trust"). Mr. Hsieh is the trustee of the Hsieh Trust and possesses the sole voting and dispositive power with respect to securities held by the Hsieh Trust.

11. Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.

12. Shares, which were previously held in a Uniform Transfers to Minor Act account, now held by an immediate family member residing in the same household as Ming Hsieh.

	/s/ Paul Kim as Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did FLGT CEO Ming Hsieh report?

Ming Hsieh reported equity grants and restricted stock unit vesting in Fulgent Genetics common stock, plus related tax-withholding share dispositions. These transactions reflect compensation and tax settlements, not open-market buying or selling activity, and update his direct and indirect ownership positions.

Were any Fulgent Genetics (FLGT) shares sold by Ming Hsieh on the open market?

The disposition entries reflect tax withholding, not open-market sales. Shares were withheld at around $23.09 and $23.01 per share to cover tax obligations from vesting restricted stock units granted in prior years as part of his compensation.

What types of stock awards did FLGT grant to Ming Hsieh?

Ming Hsieh’s transactions include performance-based restricted stock units that vested upon meeting milestones and restricted stock units that vest over three years starting after March 1, 2026. These awards are part of his long-term equity compensation in Fulgent Genetics.

How do trusts affect Ming Hsieh’s ownership in Fulgent Genetics (FLGT)?

The filing notes securities held by a Dynasty Trust, The Ming Hsieh Trust, a Uniform Transfers to Minors Act account, and an immediate family member. Hsieh has varying voting and dispositive powers; he also disclaims beneficial interest in some trust-held shares except for pecuniary interests.

What is the purpose of the tax-withholding share dispositions reported for FLGT?

The tax-withholding dispositions pay income tax due when restricted stock units vest. Instead of paying cash, a portion of newly vested shares is withheld at set prices, such as $23.09 and $23.01 per share, to satisfy the related tax obligations.

Do the reported FLGT transactions change Ming Hsieh’s role or control at the company?

The transactions update equity ownership through grants, vesting, and tax withholding but do not indicate any change in Ming Hsieh’s roles as director, Chief Executive Officer, or significant owner at Fulgent Genetics based on the information disclosed in this Form 4.